Paul Maier V

Ambrx Biopharma Inc.Eton Pharmaceuticals, Inc.International Stem Cell Corp

Insider activity · 24 months0 buys7 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 6 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (7 ops.)

€5.1M

Latest filing published 15 Sept 2026 for International Stem Cell CORP, €9,034. Read the official filing

Filing timeline

BuySale

Paul Maier V

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Paul Maier V: trading record in brief

Paul Maier V discloses dealings in 3 companies, chiefly Eton Pharmaceuticals, Inc., Ambrx Biopharma Inc. and International Stem Cell Corp. We count 11 filings; the first trade dates from 7 June 2023 and the latest from 11 September 2026.

Sales make up the whole of the open-market record (7 sales, €5.1M). Besides market trades, the filings include 1 share grant and 3 option exercises. Since January 2026: no purchases and 7 sales on the market.

The newest entry dates from 15 September 2026: an open-market sale of €9,034, in International Stem Cell Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.